Plasma 25-Hydroxyvitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer in the Nurses' Health Study

Total circulating 25-hydroxyvitamin D [25(OH)D)] has been associated with lower risk of colorectal cancer. The physiologic mechanism, however, may be more directly related to the free or bioavailable fraction of 25(OH)D, which is influenced by levels of vitamin D binding protein (VDBP). We assessed the association of prediagnosis total, free, and bioavailable 25(OH)D and VDBP with colorectal cancer risk among predominantly white women in the Nurses' Health Study (NHS) who provided a blood specimen in 1989–1990. We documented 378 cases of colorectal cancer through 2011 and matched them to 689 controls according to age and time of blood draw. We genotyped two common polymorphisms in the gene coding VDBP and calculated free and bioavailable 25(OH)D levels based on total 25(OH)D, VDBP, albumin, and their estimated genotype-specific binding affinities. Total 25(OH)D was associated with lower colorectal cancer risk (P for trend = 0.01). Compared with women in the lowest quintile of total 25(OH)D, those in the highest quintile had a multivariable-adjusted odds ratio (OR) for colorectal cancer of 0.54 [95% confidence interval (CI), 0.33–0.87]. Comparing extreme quintiles, we did not find any significant association with risk of colorectal cancer for VDBP (OR, 0.98; 95% CI, 0.65–1.47), free 25(OH)D (OR, 0.71; 95% CI, 0.46–1.10), or bioavailable 25(OH)D (OR, 0.92; 95% CI, 0.60–1.42). In conclusion, prediagnosis levels of total, but not free or bioavailable 25(OH)D, were associated with lower colorectal cancer risk. Although our findings support an inverse association of vitamin D with colorectal cancer, this association does not appear to be due to the unbound or bioavailable fraction of circulating vitamin D. Cancer Prev Res; 9(8); 664–72. ©2016 AACR.

[1]  Craig A. Mertler,et al.  Introduction to Multivariate Statistics , 2016 .

[2]  Richard D. Smith,et al.  Free 25-Hydroxyvitamin D: Impact of Vitamin D Binding Protein Assays on Racial-Genotypic Associations , 2016, The Journal of clinical endocrinology and metabolism.

[3]  Richard D. Smith,et al.  Role of Assay Type in Determining Free 25-Hydroxyvitamin D Levels in Diverse Populations. , 2016, The New England journal of medicine.

[4]  G. Beck,et al.  A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. , 2015, The New England journal of medicine.

[5]  A. Chan,et al.  Nutrients, foods, and colorectal cancer prevention. , 2015, Gastroenterology.

[6]  R. Ziegler,et al.  Serum 25‐hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial , 2015, International journal of cancer.

[7]  E. Giovannucci,et al.  Plasma 25-Hydroxyvitamin D and Risk of Colorectal Cancer after Adjusting for Inflammatory Markers , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[8]  D. Albanes,et al.  Serum Vitamin D, Vitamin D Binding Protein, and Risk of Colorectal Cancer , 2014, PloS one.

[9]  G. Carter,et al.  Assessing vitamin D status: time for a rethink? , 2014, Clinical chemistry.

[10]  E. Giovannucci,et al.  The role of vitamin D in reducing cancer risk and progression , 2014, Nature Reviews Cancer.

[11]  E. Giovannucci,et al.  A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. , 2014, Journal of the National Cancer Institute.

[12]  Peter Kraft,et al.  Joint Effects of Colorectal Cancer Susceptibility Loci, Circulating 25-Hydroxyvitamin D and Risk of Colorectal Cancer , 2014, PloS one.

[13]  B. Hollis,et al.  Vitamin D-binding protein and vitamin D in blacks and whites. , 2014, The New England journal of medicine.

[14]  Ishir Bhan,et al.  Vitamin D-binding protein and vitamin D status of black Americans and white Americans. , 2013, The New England journal of medicine.

[15]  M. Rowling,et al.  Vitamin D Transport Proteins Megalin and Disabled-2 Are Expressed in Prostate and Colon Epithelial Cells and Are Induced and Activated by All-Trans-Retinoic Acid , 2013, Nutrition and cancer.

[16]  E. Giovannucci,et al.  A prospective study of plasma inflammatory markers and risk of colorectal cancer in men , 2013, British Journal of Cancer.

[17]  R. Chun New perspectives on the vitamin D binding protein , 2012, Cell biochemistry and function.

[18]  C. Cooper,et al.  Long-term follow-up for mortality and cancer in a randomized placebo-controlled trial of vitamin D(3) and/or calcium (RECORD trial). , 2012, The Journal of clinical endocrinology and metabolism.

[19]  I. Reid,et al.  Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. , 2011, The American journal of clinical nutrition.

[20]  D. Talwar,et al.  The relation between acute changes in the systemic inflammatory response and plasma 25-hydroxyvitamin D concentrations after elective knee arthroplasty. , 2011, The American journal of clinical nutrition.

[21]  I. Bhan,et al.  Vitamin D–Binding Protein Modifies the Vitamin D–Bone Mineral Density Relationship , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[22]  E. Riboli,et al.  Meta-Analyses of Vitamin D Intake, 25-Hydroxyvitamin D Status, Vitamin D Receptor Polymorphisms, and Colorectal Cancer Risk , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[23]  E. Giovannucci,et al.  Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. , 2011, Gastroenterology.

[24]  S. Dridi,et al.  Vitamin D Binding Protein-Macrophage Activating Factor Directly Inhibits Proliferation, Migration, and uPAR Expression of Prostate Cancer Cells , 2010, PloS one.

[25]  R. Jorde,et al.  Tracking of serum 25-hydroxyvitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. , 2010, American journal of epidemiology.

[26]  R. Hayes,et al.  Long-term Variation in Serum 25-Hydroxyvitamin D Concentration among Participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[27]  B. Graubard,et al.  Prospective study of serum vitamin D and cancer mortality in the United States. , 2007, Journal of the National Cancer Institute.

[28]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[29]  W. Willett,et al.  A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. , 2007, Journal of the National Cancer Institute.

[30]  R. Recker,et al.  Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. , 2007, The American journal of clinical nutrition.

[31]  M. Speeckaert,et al.  Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[32]  E. Giovannucci Calcium plus vitamin D and the risk of colorectal cancer. , 2006, The New England journal of medicine.

[33]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[34]  John Robbins,et al.  Calcium plus vitamin D supplementation and the risk of colorectal cancer. , 2006, The New England journal of medicine.

[35]  S. Hankinson,et al.  Plasma vitamin D metabolites and risk of colorectal cancer in women. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[36]  E. Giovannucci,et al.  Plasma 1,25-Dihydroxy- and 25-Hydroxyvitamin D and Subsequent Risk of Prostate Cancer , 2004, Cancer Causes & Control.

[37]  J. Constans,et al.  Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP) , 1993, Human Genetics.

[38]  A. Braun,et al.  Molecular analysis of the gene for the human vitamin-D-binding protein (group-specific component): allelic differences of the common genetic GC types , 1992, Human Genetics.

[39]  R. Doll,et al.  Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial , 2003, BMJ : British Medical Journal.

[40]  R. D'Amato,et al.  Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. , 2003, Neoplasia.

[41]  F. Greene AJCC cancer staging handbook , 2002 .

[42]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[43]  P. White,et al.  The Multifunctional Properties and Characteristics of Vitamin D-binding Protein , 2000, Trends in Endocrinology & Metabolism.

[44]  Henrik Vorum,et al.  An Endocytic Pathway Essential for Renal Uptake and Activation of the Steroid 25-(OH) Vitamin D3 , 1999, Cell.

[45]  J. Manson,et al.  The Nurses' Health Study: 20-year contribution to the understanding of health among women. , 1997, Journal of women's health.

[46]  G A Colditz,et al.  Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[47]  J. Haddad Plasma vitamin D-binding protein (Gc-globulin): Multiple tasks , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[48]  R. Kumashiro,et al.  Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of beta-galactosidase of B cells and sialidase of T cells. , 1993, Journal of immunology.

[49]  D L Streiner,et al.  An Introduction to Multivariate Statistics , 1993, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[50]  H. Perez,et al.  Identification of the C5a des Arg cochemotaxin. Homology with vitamin D-binding protein (group-specific component globulin). , 1988, The Journal of clinical investigation.

[51]  R. Kew,et al.  Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. , 1988, The Journal of clinical investigation.

[52]  J. Haddad,et al.  Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. , 1986, The Journal of clinical endocrinology and metabolism.